Want to see FR:ABVX full AI Analyst Report?
Top Page
Abivax SA
(ABVX)
Select Model
Select Model
Rating:44Neutral
Price Target:
€79.00
▼(-20.96% Downside)
Action:Reiterated
Date:09/25/26
The score is primarily held back by weak financial performance—ongoing large losses, unstable revenue (including a 2025 drop to zero), and persistent negative free cash flow—despite an improved 2025 balance sheet with low leverage. Technicals add further pressure due to a broad downtrend and negative momentum indicators. Valuation provides limited support because earnings are negative and there is no dividend yield.
Positive Factors
Improved Balance Sheet
Lower leverage and a larger equity base improve financial flexibility compared with prior years. This can support continued clinical development and provide a stronger buffer for operations, although the company still depends on financing because profitability has not been achieved.
Negative Factors
No Commercial Revenue
Abivax currently lacks recurring product sales to fund its operations, so its financial profile depends on successful clinical development and eventual regulatory approval. Until commercialization occurs, revenue visibility remains limited and operating costs must be funded externally.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Balance Sheet
Lower leverage and a larger equity base improve financial flexibility compared with prior years. This can support continued clinical development and provide a stronger buffer for operations, although the company still depends on financing because profitability has not been achieved.
Read all positive factors
Abivax SA (ABVX) vs. iShares MSCI France ETF (EWQ)
Market Cap
€7.32B
Dividend YieldN/A
Average Volume (3M)150.46K
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue GrowthN/A
EPS GrowthN/A
CountryFR
Employees80
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.71
Shares Outstanding87,350,044
10 Day Avg. Volume152,303
30 Day Avg. Volume150,455
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)18.39
Price to Sales (P/S)0.00
P/FCF Ratio-51.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€132.00Price Target Upside32.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.74
Revenue Forecast (FY)€3.80M
Abivax SA Business Overview & Revenue Model
Company Description
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ...
How the Company Makes Money
Abivax SA does not have a disclosed commercial product revenue stream and, as a clinical-stage biopharmaceutical company, its operations are primarily funded through external financing rather than sales. The company’s cash inflows typically come f...
Abivax SA Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -2.02M | 0.00 | 10.79M | 4.62M | 4.58M | 37.00K |
| Gross Profit | -3.09M | -1.07M | 10.79M | 4.49M | 4.51M | -119.00K |
| EBITDA | -278.36M | -249.55M | -167.68M | -133.21M | -53.31M | -42.20M |
| Net Income | -352.75M | -336.10M | -176.24M | -147.74M | -60.74M | -42.45M |
Balance Sheet | ||||||
| Total Assets | 462.21M | 584.34M | 205.23M | 327.06M | 73.35M | 110.36M |
| Cash, Cash Equivalents and Short-Term Investments | 410.68M | 530.38M | 144.22M | 260.99M | 26.95M | 60.70M |
| Total Debt | 1.21M | 32.09M | 97.36M | 55.46M | 39.16M | 53.45M |
| Total Liabilities | 95.94M | 129.14M | 164.64M | 131.05M | 71.47M | 81.59M |
| Stockholders Equity | 366.27M | 455.20M | 40.58M | 196.01M | 7.19M | 25.93M |
Cash Flow | ||||||
| Free Cash Flow | -147.65M | -162.23M | -154.72M | -97.39M | -69.55M | -47.30M |
| Operating Cash Flow | -147.46M | -162.09M | -154.07M | -97.13M | -65.58M | -45.66M |
| Investing Cash Flow | 4.25M | -13.72M | 15.76M | -8.10M | -3.73M | -1.46M |
| Financing Cash Flow | 564.11M | 553.80M | 28.21M | 335.29M | 32.21M | 82.68M |
Abivax SA Technical Analysis
Negative
99.95
Price Trends
100.82
Negative
101.47
Negative
102.03
Negative
Market Momentum
-5.22
Positive
31.72
Neutral
21.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABVX, the sentiment is Negative. The current price of 99.95 is above the 20-day moving average (MA) of 92.79, below the 50-day MA of 100.82, and below the 200-day MA of 102.03, indicating a bearish trend. The MACD of -5.22 indicates Positive momentum. The RSI at 31.72 is Neutral, neither overbought nor oversold. The STOCH value of 21.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ABVX.
Abivax SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | €152.81M | -2.70 | 152.56% | ― | -29.48% | 7.91% | |
47 Neutral | €202.87M | -4.32 | -29.36% | ― | 189.81% | 38.50% | |
47 Neutral | €509.58M | -3.02 | -152.15% | ― | -27.19% | -117.39% | |
44 Neutral | €7.32B | -17.95 | -85.88% | ― | ― | ― | |
43 Neutral | €634.32M | -2.95 | -119.47% | ― | ― | 41.33% | |
41 Neutral | €91.93M | -2.15 | -94.14% | ― | -5.98% | -8.67% |
* General Sector Average
FR:ABVX
Abivax SA
83.85
12.75
17.93%
FR:IPH
Innate Pharma SA
1.37
-0.37
-21.38%
FR:DBV
DBV Technologies
2.02
0.17
8.96%
FR:TNG
Transgene
0.73
-0.40
-35.49%
FR:VLA
Valneva
2.69
-2.40
-47.21%
FR:ALCLS
Cellectis SA
1.27
-1.51
-54.28%
Abivax SA Corporate Events
Abivax Updates Share Capital and Voting Rights Structure as of August 31, 2026
Sep 25, 2026
Abivax reported that, as of August 31, 2026, its share capital consists of 87,271,525 shares, corresponding to 88,526,782 theoretical and exercisable voting rights under French market regulations. The disclosure, made in line with requirements of ...
Abivax bolsters leadership and balance sheet as obefazimod nears commercialization
Sep 21, 2026
Abivax has overhauled its leadership team as it prepares for potential commercialization of obefazimod, appointing Chris Rabbat as Chief Medical Officer and Tim Kelly as Chief Technical Officer. These changes are designed to bolster medical, CMC, ...
Abivax Updates Share Capital and Voting Rights as of July 31, 2026
Aug 12, 2026
Abivax reported that as of July 31, 2026, its share capital consists of 87,253,797 shares, corresponding to 88,512,554 theoretical and exercisable voting rights under French market regulations. The disclosure, part of routine regulatory transparen...
Abivax Gains FDA Alignment on Obefazimod NDA Plan for Ulcerative Colitis
Jul 30, 2026
Abivax has received a positive response from the U.S. Food and Drug Administration following its pre-New Drug Application interactions for obefazimod in adults with moderately to severely active ulcerative colitis. The agency’s constructive ...
Abivax bolsters commercial leadership ahead of potential U.S. launch of obefazimod
Jul 23, 2026
Abivax has reinforced its commercial organization with four senior hires covering global marketing, patient services, sales and commercial operations, and market access and pricing. The appointments bring extensive experience in immunology, gastro...
Abivax Raises $920 Million in U.S. ADS Offering, Extending Cash Runway to 2029
Jul 7, 2026
Abivax has completed a U.S. public offering of 7,360,000 American Depositary Shares, including full exercise of the underwriters’ over-allotment option, raising gross proceeds of about $920 million and estimated net proceeds of roughly $874 ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.